ARTICLE | Politics & Policy

FDA user fees dropping in FY17

July 27, 2016 7:00 AM UTC

FDA unveiled FY17 user fee rates for drugs and biosimilars that will be lower than those the agency set for FY16.

The fee for drug applications containing clinical data will be $2.04 million in FY17, compared to $2.37 million in FY16. The new fee for applications that do not require clinical data, and for supplemental applications requiring clinical data, will be $1.02 million, down from $1.19 million in FY16. ...